Pharmaceutical Technology

JANUARY 29, 2024

The rapid sequencing of the SARS-CoV-2 and the subsequent development of mRNA vaccines led to the authorisation of the first of these vaccines in late 2020.

Vaccines 111

Vaccines 111

ALiEM - Pharm Pearls

JANUARY 12, 2024

A 42-year old Bengali man with a history of hyperlipidemia presented to the Emergency Department with facial swelling, diffuse rash, renal insufficiency and proteinuria after receiving his COVID-19 vaccine (Moderna) booster dose. Erythema multiforme has been reported as a cutaneous reaction after the COVID-19 mRNA vaccine.

Vaccines 130

Vaccines 130

STAT

MARCH 28, 2024

While an increasingly anxious world watched a new coronavirus spread across the globe in early 2020, veteran immunologist Rafi Ahmed quickly grasped that his field was about to experience something truly extraordinary.

Immunity 363

Immunity Immunization Vaccines 363

Express Pharma

JANUARY 29, 2024

The global messenger ribonucleic acid (mRNA) vaccines market currently consists entirely of vaccines for COVID-19. The rapid sequencing of the SARS-CoV-2 viral genome and the subsequent development of mRNA vaccines in response to the pandemic led to the authorisation of the first of these vaccines in December 2020.

Vaccines 103

Vaccines 103

STAT

MAY 14, 2024

clinical trial for the AstraZeneca Covid-19 vaccine is suing the company, claiming it left her “permanently disabled,” The Telegraph writes. made vaccine was tested in clinical trials but never approved for use. An American woman who took part in the U.S. Her lawsuit is thought to be the first of its kind in the U.S.,

Vaccines 189

Vaccines 189

STAT

MAY 23, 2023

WASHINGTON — The incarcerated people at Federal Medical Center Devens should have been some of the first to receive the Covid vaccines, back when they first came out in December 2020. At the time, the country was prioritizing high-risk people in high-risk settings, like older Americans in nursing homes.

Nursing Homes 260

Nursing Homes Vaccines 260

European Pharmaceutical Review

AUGUST 2, 2023

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax is now the ninth vaccine to be authorised by the UK’s independent medicines regulator to treat the virus. The vaccine demonstrated a strong immune response in the trial.

Vaccines 96

Vaccines Immunity Immunization 96

STAT

OCTOBER 2, 2023

Overcoming a lack of broader interest in their work and scientific challenges, Katalin Karikó and Drew Weissman made key discoveries about messenger RNA that enabled scientific teams to start developing the tool into therapies, immunizations, and — as the pandemic spread in 2020 — vaccines targeting the SARS-CoV-2 coronavirus.

Immunity 364

Immunity Immunization Vaccines 364

Express Pharma

OCTOBER 25, 2023

With influenza season well underway, vaccination campaigns are in full force in the northern hemisphere. This will reshape the global influenza vaccine market for the upcoming seasons, says GlobalData. Kurdach continues, “When the actual composition of vaccines will revert to trivalent formulations remains another question.

Vaccines 98

Vaccines 98

European Pharmaceutical Review

NOVEMBER 1, 2023

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development. 1 WHO’s analysis was stark.

Vaccines 95

Vaccines Immunity Immunization Drug Development 95

Express Pharma

MARCH 23, 2023

China has approved its first domestically developed mRNA vaccine against COVID-19, CSPC Pharmaceutical Group said. China, whose home-grown vaccines are seen as less effective than the Moderna and Pfizer-BioNTech mRNA shots, has been racing to develop vaccines using messenger RNA (mRNA) technology since early 2020.

Vaccines 108

Vaccines 108

European Pharmaceutical Review

AUGUST 16, 2022

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated version of Moderna’s COVID-19 vaccine, Spikevax, that targets two coronavirus variants as a booster. The regulator confirmed that the vaccine meets its standards of safety, quality and effectiveness. 1) and the original 2020 strain.

Vaccines 99

Vaccines Immunity Immunization 99

European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 97

Vaccines Communication Immunity Immunization 97

Express Pharma

APRIL 7, 2023

People exposed to higher levels of air pollution before the pandemic had lower antibody responses to COVID-19 vaccines, according to a study. Air pollutants have been shown to affect immune responses, so in this study we wished to determine whether air pollution also affects antibody responses to COVID-19 vaccines,” said Kogevinas.

Vaccines 102

Vaccines Immunity Immunization Diabetes 102

Pharmaceutical Technology

APRIL 11, 2023

The US government is reportedly investing more than $5bn in a programme to accelerate the development of new Covid-19 vaccines and treatments. Health experts have lent their support to the new programme as the existing vaccines may not be as effective against future virus threats.

Vaccines 105

Vaccines Immunity Immunization 105

Eye on FDA

JANUARY 6, 2021

During 2020, FDA was able to approve 53 – not surpassing the 2018 all time record of 59, but certainly an admirable second place. Notably, the 2020 NME approvals included 22 related to oncology, with 2 new GIST treatments, 3 in breast cancer and 2 approvals in prostate cancer. That, however, was not really the case.

Compounding 82

Compounding Vaccines 82

pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. over the last five years. A broad front.

Vaccines 132

Vaccines Immunity Immunization Compounding 132

Pharmaceutical Technology

SEPTEMBER 7, 2022

Indian company Bharat Biotech International has secured approval from Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for its intranasal Covid-19 vaccine, iNCOVACC (BBV154), for usage in people aged 18 years and older. It is formulated to permit intranasal delivery via nasal drops.

Vaccines 105

Vaccines 105

pharmaphorum

JUNE 21, 2021

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot. Among the 25-strong group given the vaccine on its own, there was one patient who had a complete remission of tumours that had spread from the original site.

Vaccines 145

Vaccines Immunity Immunization 145

pharmaphorum

OCTOBER 12, 2022

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. As we all know, cancer vaccines have had a rough history. The post Merck gets on board with Moderna cancer vaccine in $250m deal appeared first on.

Vaccines 103

Vaccines 103

Outsourcing Pharma

MARCH 3, 2021

The 2020 Pfizer/BioNTech COVID-19 vaccine trial recruited more than 44,000 participants and reached submission for emergency authorization in 248 days: showing unprecedented speed and agility in the context of a global pandemic.

Vaccines 130

Vaccines 130

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Vaccines 98

Vaccines Immunity Immunization Process Improvement 98

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. However, 2020 did not provide a definitive answer to the biggest question in neurology – which is whether pharma can produce a marketable that can slow the onset of Alzheimers.

Chemotherapy 80

Chemotherapy Compounding Vaccines 80

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology. Antibodies cover the pathogen of the virus and neutralise it.

Vaccines 93

Vaccines Immunity Immunization 93

pharmaphorum

MARCH 16, 2021

European regulators questioned the integrity of early batches of Pfizer/BioNTech’s mRNA vaccine, although the matter was resolved before approval, according to information leaked online following a cyberattack. As it conducted its analysis of the vaccine in December, the European Medicines Agency’s systems were targeted by unknown hackers.

Vaccines 136

Vaccines Documentation 136

Pharmaceutical Technology

SEPTEMBER 15, 2022

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccines 108

Vaccines Drug Pricing Biosimilars Documentation 108

pharmaphorum

JUNE 29, 2022

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Pfizer’s RSVpreF vaccine is in hot pursuit of GSK’s shot, with results due to be reported very soon from the phase 3 RENOIR trial in older adults.

Vaccines 94

Vaccines 94

Pharmaceutical Technology

FEBRUARY 21, 2023

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast. Comirnaty is the first globally approved Covid-19 vaccine.

Vaccines 98

Vaccines 98

Eye on FDA

MARCH 5, 2023

Note these numbers cover meetings about drug applications only, not including vaccines or cellular therapies. That said, beginning in 2020 meetings began skewing to more negative outcomes and 2022 was the first year where the number of negative outcomes outweighed the number of positive outcomes.

Vaccines 72

Vaccines 72

STAT

OCTOBER 25, 2022

As MacArthur Foundation fellow Jennifer Richeson noted in The Atlantic in 2020, Americans love to perpetuate narratives of racial progress , regardless of whether that narrative is aligned with reality. We saw this in a recent New York Times essay that claimed the change in Covid-19 death rates is a laudable example of the U.S.

Vaccines 284

Vaccines 284

European Pharmaceutical Review

AUGUST 22, 2022

UNICEF has awarded GSK the first ever contract for the supply of a malaria vaccine. According to UNICEF, nearly half a million children died from malaria in Africa in 2020, at a rate of one child death per minute, so the supply contact could save thousands of lives every year. Under the $170 million (€167.4

Vaccines 93

Vaccines 93

pharmaphorum

DECEMBER 22, 2020

The trials and tribulations of 2020 have brought the vital role of research, pharma, and biotech into sharp focus. But how has the push to develop treatments and vaccines for SARS-CoV-2 affected the industry’s commitment to patient centricity? The post 2020 in review: COVID-19 and patient centric clinical trials appeared first on.

Vaccines 69

Vaccines 69

Pharmaceutical Technology

AUGUST 15, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorisation for Moderna ’s Covid-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron), for use in adults aged 18 years and above. It comprises mRNA-1273 (Spikevax) and a vaccine candidate that acts on the SARS-CoV-2 virus’ BA.1

Vaccines 85

Vaccines Immunity Immunization 85

STAT

APRIL 19, 2023

The calamity of March 2020 arrived two years later for pediatric units.

Vaccines 216

Vaccines Hospitals 216

pharmaphorum

FEBRUARY 1, 2021

The diplomatic row that broke out last week over the supply of AstraZeneca’s vaccine to Europe appears to have cooled after the UK pharma agreed to supply an extra nine million doses. Step forward on vaccines. The post AstraZeneca to supply nine million more vaccines to EU appeared first on.

Vaccines 115

Vaccines 115

STAT

MARCH 6, 2023

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine.

Vaccines 244

Vaccines Bioethics Immunity Immunization 244

Pharma Times

SEPTEMBER 10, 2020

The proposed deal covers the initial supply of 200 million doses and an option to purchase an additional 100 million, with deliveries starting by the end of 2020, if the vaccine is approved

Vaccines 100

Vaccines 100